Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 2Phase 4 1

Status

Completed 7

Sponsor Class

OTHER 48NIH 21NETWORK 9INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 7Classical hematology 2

Conditions

Neutropenia 11Leukemia, Myeloid, Acute 9Breast Neoplasms 7Lymphoma, Non-Hodgkin 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Leukemia 4Triple Negative Breast Neoplasms 3Multiple Myeloma 3Leukemia, Biphenotypic, Acute 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Plasmacytoma 2Paraproteinemias 2Pancreatic Neoplasms 2Neoplasms 2Leukemia, Plasma Cell 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Febrile Neutropenia 2Anemia, Refractory, with Excess of Blasts 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neutropenia in Breast Cancer 1Myelodysplastic Syndromes 1Medulloblastoma 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × Filgrastim × Clear all
NCT04174599 2025-04-20

Study to Compare the Efficacy and Safety of F-627 and GRAN®

EVIVE Biotechnology

Phase 3 Completed
242 enrolled 41 charts
Breast

Breast Neoplasms, Neutropenia

NCT03343145 2020-12-28

A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients

Dong-A ST Co., Ltd.

Phase 3 Completed
143 enrolled
Breast

Breast Neoplasms, Neutropenia

NCT01416389 2019-09-18

A Study of LY2523355 in Participants With Breast Cancer

Eli Lilly and Company

Phase 2 Completed
39 enrolled 16 charts
Breast

Breast Neoplasms, Neoplasms, Recurrence

NCT01569087 2016-12-05

Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer

Biocad

Phase 2 Completed
60 enrolled 17 charts
BreastClassical hematology

Breast Neoplasms, Neutropenia, Febrile Neutropenia

NCT02104830 2016-10-24

Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients

Biocad

Phase 3 Completed
135 enrolled 18 charts
BreastClassical hematology

Breast Neoplasms, Neutropenia, Febrile Neutropenia

NCT02805153 2016-06-20

PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Phase 4 Completed
215 enrolled
Breast

Breast Neoplasms

NCT01519700 2015-05-06

PIONEER

Sandoz

Phase 3 Completed
218 enrolled 15 charts
Breast

Breast Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡